{"eventGroups":[{"deathsNumAffected":8,"deathsNumAtRisk":29,"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: Patients receive fludarabine phosphate intravenously (IV) on days -4 to -2 (except for patients who had prior autologous HCT or equivalent high-dose therapy without HCT) and undergo low-dose total body irradiation (TBI) on day 0.\n\nTRANSPLANT: Patients undergo donor PBSC transplant on day 0.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"EG000","otherNumAffected":6,"otherNumAtRisk":29,"seriousNumAffected":1,"seriousNumAtRisk":29,"title":"Primary - Reg A (Flu/TBI)"},{"deathsNumAffected":2,"deathsNumAtRisk":5,"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: Patients will undergo low-dose total body irradiation (TBI) on day 0.\n\nTRANSPLANT: Patients undergo donor PBSC transplant on day 0.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"EG001","otherNumAffected":1,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Primary - Reg B (TBI Alone)"},{"deathsNumAffected":3,"deathsNumAtRisk":12,"description":"NONMYELOABLATIVE PREPARATIVE REGIMEN: The preparative regimen and immunosuppression after transplant will be according to respective protocol or treatment plan.\n\nPOST-GRAFTING IMMUNOSUPPRESSION: Patients receive CSP PO twice daily (BID) on days -3 to 56 with taper to day 180. Patients also receive mycophenolate mofetil (MMF) PO BID or IV every 12 hours on days 0-27.","id":"EG002","otherNumAffected":2,"otherNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"title":"Adjunct"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Acute kidney injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Allergic reaction"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":5,"numEvents":1},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Delirium"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Hypertension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Hypertriglyceridemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":12,"numEvents":1}],"term":"Hypophosphatemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Leukoencephalopathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Lung infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":12,"numEvents":1}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":12,"numEvents":1}],"term":"Non-cardiac chest pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Pleural effusion"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Pneumothorax"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Thromboembolic event"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":29,"numEvents":0},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":1,"numAtRisk":12,"numEvents":1}],"term":"Vomiting"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":29,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":5,"numEvents":0},{"groupId":"EG002","numAffected":0,"numAtRisk":12,"numEvents":0}],"term":"Duodenal ulcer"}],"timeFrame":"AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200; All-Cause Mortality: Conditioning through 1 Year."}